331 related articles for article (PubMed ID: 31939435)
1. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Yang M; Li J; Sun R; Wang Y; Xu H; Yang B; Wu X; Yu L
J Cancer Res Ther; 2019; 15(7):1541-1546. PubMed ID: 31939435
[TBL] [Abstract][Full Text] [Related]
2. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis.
Dong Y; Wang Y; Ma RL; Liu M; Gao JZ; Su WY; Yan L; Sun JJ
J Thromb Thrombolysis; 2019 Oct; 48(3):400-412. PubMed ID: 31062143
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials.
Brunetti ND; Tricarico L; Correale M; De Gennaro L; Santoro F; Ieva R; Di Biase M
J Thromb Thrombolysis; 2020 Aug; 50(2):305-310. PubMed ID: 31654194
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
6. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
[TBL] [Abstract][Full Text] [Related]
7. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
[TBL] [Abstract][Full Text] [Related]
8. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
9. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis.
Wu T; Xia X; Chen W; Fu J; Zhang J
J Clin Pharm Ther; 2020 Aug; 45(4):602-608. PubMed ID: 32449992
[TBL] [Abstract][Full Text] [Related]
10. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Ferrante N; Otten HM; Cuccurullo F; Rutjes AW
Cochrane Database Syst Rev; 2012 Feb; (2):CD008500. PubMed ID: 22336844
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
Murphy AC; Koshy AN; Farouque O; Yeo B; Raman J; Kearney L; Yudi MB
Heart Lung Circ; 2022 May; 31(5):716-725. PubMed ID: 34896013
[TBL] [Abstract][Full Text] [Related]
13. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
14. Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis.
Nugroho Eko Putranto J; Wardhana A; Noor YA; Lambok Marnala Yosua Siahaan P; Al Farabi MJ
F1000Res; 2021; 10():1257. PubMed ID: 35136585
[No Abstract] [Full Text] [Related]
15. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
Li A; Garcia DA; Lyman GH; Carrier M
Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin is associated with lower venous thromboembolism events than factor Xa inhibitors in patients with severe blunt trauma: a cohort study from the Trauma Quality Improvement Program.
Chan SY; Huang JF; Cheng CT; Hsu CP; Liao CH; Fu CY
Int J Surg; 2024 Jan; 110(1):280-286. PubMed ID: 37738013
[TBL] [Abstract][Full Text] [Related]
17. Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studies.
Hussain MR; Ali FS; Verghese D; Myint PT; Ahmed M; Gong Z; Gerais Y; Siddiqui M; Lin JJ; Troy K
Crit Rev Oncol Hematol; 2022 Jan; 169():103526. PubMed ID: 34838704
[TBL] [Abstract][Full Text] [Related]
18. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
20. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis.
Neumann I; Rada G; Claro JC; Carrasco-Labra A; Thorlund K; Akl EA; Bates SM; Guyatt GH
Ann Intern Med; 2012 May; 156(10):710-9. PubMed ID: 22412038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]